Literature DB >> 1159684

3-Hydroxymethyl-s-triazolo[3,4-a]phthalazine, a novel urinary hydralazine metabolite in man.

H Zimmer, R Glaser, J Kokosa, D A Garteiz, E V Hess, A Litwin.   

Abstract

The elucidation of the structure of a new major metabolic product of hydralazine, 3-hydroxymethyl-s-triazolo[3,4-a]-phthalazine, is described. The structures of several other previously described metabolites of the drug, phthalazone, s-triazolo[3,4-a]phthalazine, and 3-methyl-s-triazolo[3,4-a]phthalazine, are confirmed. A metabolic pathway of hydralazine is also proposed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159684     DOI: 10.1021/jm00244a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

3.  Studies on hydralazine. III. Bioavailability of hydralazine in man.

Authors:  T Talseth
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

4.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

5.  Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function.

Authors:  T Talseth
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.